6.
Rodero M, Crow Y
. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med. 2016; 213(12):2527-2538.
PMC: 5110029.
DOI: 10.1084/jem.20161596.
View
7.
Li Z, Yu T, Morishima M, Pao A, LaDuca J, Conroy J
. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum Mol Genet. 2007; 16(11):1359-66.
DOI: 10.1093/hmg/ddm086.
View
8.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S
. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8.
PMC: 7102627.
DOI: 10.1016/j.cell.2020.02.052.
View
9.
Clift A, Coupland C, Keogh R, Hemingway H, Hippisley-Cox J
. COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. Ann Intern Med. 2020; 174(4):572-576.
PMC: 7592804.
DOI: 10.7326/M20-4986.
View
10.
Paoloni-Giacobino A, Chen H, Peitsch M, Rossier C, Antonarakis S
. Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 1997; 44(3):309-20.
DOI: 10.1006/geno.1997.4845.
View
11.
Saji T
. Clinical characteristics of pulmonary arterial hypertension associated with Down syndrome. Pediatr Int. 2014; 56(3):297-303.
DOI: 10.1111/ped.12349.
View
12.
Kusters M, Manders N, de Jong B, van Hout R, Rijkers G, de Vries E
. Functionality of the pneumococcal antibody response in Down syndrome subjects. Vaccine. 2013; 31(52):6261-5.
DOI: 10.1016/j.vaccine.2013.09.070.
View
13.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z
. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141.
PMC: 8454663.
DOI: 10.1016/j.xinn.2021.100141.
View
14.
Waugh K, Minter R, Baxter J, Chi C, Galbraith M, Tuttle K
. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nat Genet. 2023; 55(6):1034-1047.
PMC: 10260402.
DOI: 10.1038/s41588-023-01399-7.
View
15.
Gensous N, Bacalini M, Franceschi C, Garagnani P
. Down syndrome, accelerated aging and immunosenescence. Semin Immunopathol. 2020; 42(5):635-645.
PMC: 7666319.
DOI: 10.1007/s00281-020-00804-1.
View
16.
Xing Z, Li Y, Pao A, Bennett A, Tycko B, Mobley W
. Mouse-based genetic modeling and analysis of Down syndrome. Br Med Bull. 2016; 120(1):111-122.
PMC: 5146682.
DOI: 10.1093/bmb/ldw040.
View
17.
Bruijn M, van der Aa L, van Rijn R, Bos A, van Woensel J
. High incidence of acute lung injury in children with Down syndrome. Intensive Care Med. 2007; 33(12):2179-82.
PMC: 2092441.
DOI: 10.1007/s00134-007-0803-z.
View
18.
Zhang Q, Bastard P, Cobat A, Casanova J
. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022; 603(7902):587-598.
PMC: 8957595.
DOI: 10.1038/s41586-022-04447-0.
View
19.
Tilley A, Walters M, Shaykhiev R, Crystal R
. Cilia dysfunction in lung disease. Annu Rev Physiol. 2014; 77:379-406.
PMC: 4465242.
DOI: 10.1146/annurev-physiol-021014-071931.
View
20.
Huls A, Costa A, Dierssen M, Baksh R, Bargagna S, Baumer N
. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine. 2021; 33:100769.
PMC: 7897934.
DOI: 10.1016/j.eclinm.2021.100769.
View